| Rodent models for urodynamic investigation KE Andersson, R Soler, C Füllhase Neurourology and urodynamics 30 (5), 636-646, 2011 | 213 | 2011 |
| The prevalence of lower urinary tract symptoms (LUTS) in Brazil: Results from the epidemiology of LUTS (Brazil LUTS) study R Soler, CM Gomes, MA Averbeck, M Koyama Neurourology and Urodynamics 37 (4), 1356-1364, 2018 | 100 | 2018 |
| Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms R Soler, KE Andersson, MB Chancellor, CR Chapple, WC de Groat, ... European urology 64 (4), 610-621, 2013 | 80 | 2013 |
| Novel keratin (KeraStat™) and polyurethane (Nanosan®-Sorb) biomaterials are hemostatic in a porcine lethal extremity hemorrhage model LR Burnett, JG Richter, MB Rahmany, R Soler, JA Steen, G Orlando, ... Journal of Biomaterials Applications 28 (6), 869-879, 2014 | 64 | 2014 |
| Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease R Soler, C Füllhase, A Hanson, L Campeau, C Santos, KE Andersson The Journal of urology 187 (4), 1491-1497, 2012 | 58 | 2012 |
| Urine is necessary to provoke bladder inflammation in protamine sulfate induced urothelial injury R Soler, H Bruschini, MP Freire, MT Alves, M Srougi, V Ortiz The Journal of urology 180 (4), 1527-1531, 2008 | 50 | 2008 |
| Bladder dysfunction in a new mutant mouse model with increased superoxide—lack of nitric oxide? R Soler, C Füllhase, B Lu, CE Bishop, KE Andersson The Journal of urology 183 (2), 780-785, 2010 | 43 | 2010 |
| Urinary glycosaminoglycans as biomarker for urothelial injury: is it possible to discriminate damage from recovery? R Soler, H Bruschini, JR Martins, JL Dreyfuss, NO Camara, MT Alves, ... Urology 72 (4), 937-942, 2008 | 42 | 2008 |
| Development of bladder dysfunction in a rat model of dopaminergic brain lesion R Soler, C Füllhase, C Santos, KE Andersson Neurourology and urodynamics 30 (1), 188-193, 2011 | 40 | 2011 |
| Urinary glycosaminoglycans excretion and the effect of dimethyl sulfoxide in an experimental model of non-bacterial cystitis R Soler, H Bruschini, JC Truzzi, JR Martins, NO Camara, MT Alves, ... International braz j urol 34, 503-511, 2008 | 37 | 2008 |
| Vascular therapy for radiation cystitis R Soler, A Vianello, C Füllhase, Z Wang, A Atala, S Soker, JJ Yoo, ... Neurourology and urodynamics 30 (3), 428-434, 2011 | 33 | 2011 |
| Bladder dysfunction and parkinsonism: current pathophysiological understanding and management strategies L Campeau, R Soler, KE Andersson Current urology reports 12, 396-403, 2011 | 31 | 2011 |
| Does the less aggressive multimodal approach of treating bladder-prostate rhabdomyosarcoma preserve bladder function? R Soler, A Macedo, H Bruschini, FÍO Puty, E Caran, A Petrilli, G Garrone, ... The Journal of urology 174 (6), 2343-2346, 2005 | 28 | 2005 |
| New strategies in treating male lower urinary tract symptoms C Füllhase, R Soler, C Gratzke Current Opinion in Urology 24 (1), 29-35, 2014 | 27 | 2014 |
| Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction C Füllhase, R Soler, C Gratzke, M Brodsky, GJ Christ, KE Andersson BJU international 106 (2), 287-293, 2010 | 26 | 2010 |
| Regenerative medicine strategies for treatment of neurogenic bladder R Soler, C Fullhase, A Atala Therapy 6 (2), 177, 2009 | 24 | 2009 |
| Effects of allogeneic bone marrow derived mesenchymal stromal cell therapy on voiding function in a rat model of Parkinson disease L Campeau, R Soler, S Sittadjody, R Pareta, M Nomiya, M Zarifpour, ... The Journal of urology 191 (3), 850-859, 2014 | 22 | 2014 |
| Urothelial effects of oral agents for overactive bladder KE Andersson, C Fullhase, R Soler Current urology reports 9 (6), 459-464, 2008 | 19 | 2008 |
| Impact of OAB symptoms on work, quality of life and treatment-seeking behavior in Brazil CM Gomes, MA Averbeck, M Koyama, R Soler Current Medical Research and Opinion 36 (8), 1403-1415, 2020 | 18 | 2020 |
| Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41‐2272 and BAY 60‐2770 alone or in combination with a phosphodiesterase type 5 … C Füllhase, M Hennenberg, P Sandner, F Strittmatter, C Niedworok, ... Neurourology and Urodynamics 34 (8), 787-793, 2015 | 17 | 2015 |
